Current and future perspectives of Fanconi Anemia treatment - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue (Article De Synthèse) Blood Reviews Année : 2023

Current and future perspectives of Fanconi Anemia treatment

Résumé

Fanconi anemia (FA) is a rare inherited disorder that mainly affects the bone marrow. This condition causes decreased production of all types of blood cells. FA is caused by a defective repair of DNA interstrand crosslinks, and to date mutations in 22 different genes (FANCA-FANCW) have been linked to the disease. Advances in science and molecular biology have provided new insight between FA gene mutations and the severity of clinical manifestations. Here, we will highlight the current and promising therapeutic options for this rare disease. The current standard treatment for FA patients is hematopoietic stem cell transplantation, a treatment associated to exposure to radiation or chemotherapy, immunological complications, plus opportunistic infections from prolonged immune incompetence or increased risk of morbidity. New arising treatments include gene addition therapy, genome editing using CRISPR-Cas9 nuclease, and hematopoietic stem cell generation from induced pluripotent stem cells. Finally, we will also discuss the revolutionary developments in mRNA therapeutics as an opportunity for this disease.
Fichier principal
Vignette du fichier
Review FA therapies.pdf (262.75 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04260951 , version 1 (26-10-2023)

Identifiants

Citer

Elena Martínez-Balsalobre, Jean-Hugues Guervilly, Ana Belen Pérez-Oliva, Jenny van Asbeck-van der Wijst, Lachaud Christophe. Current and future perspectives of Fanconi Anemia treatment. Blood Reviews, 2023, 6, pp.1. ⟨10.1186/1877-6566-6-1⟩. ⟨hal-04260951⟩

Collections

CNRS UNIV-AMU CRCM
111 Consultations
68 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More